{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:01:13Z","timestamp":1778713273143,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bellicum Pharmaceuticals, Inc.","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00262-017-2027-6","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T14:44:48Z","timestamp":1497278688000},"page":"1345-1357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer"],"prefix":"10.1007","volume":"66","author":[{"given":"Guru","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"McMannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamatha R.","family":"Seethammagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan M. C.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa K.","family":"Dancsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Lapteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Slawin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"key":"2027_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512. doi:10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520. doi:10.1056\/NEJMoa041318","journal-title":"N Engl J Med"},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422. doi:10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"key":"2027_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154. doi:10.1016\/S0140-6736(10)61389-X","journal-title":"Lancet"},{"key":"2027_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005. doi:10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"key":"2027_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197. doi:10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"key":"2027_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223. doi:10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"key":"2027_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148. doi:10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"key":"2027_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433. doi:10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"key":"2027_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422. doi:10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"key":"2027_CR11","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/cncr.24429","volume":"115","author":"CS Higano","year":"2009","unstructured":"Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670\u20133679. doi:10.1002\/cncr.24429","journal-title":"Cancer"},{"key":"2027_CR12","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/80498","volume":"6","author":"T Kikuchi","year":"2000","unstructured":"Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG (2000) Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med 6:1154\u20131159. doi:10.1038\/80498","journal-title":"Nat Med"},{"key":"2027_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nm1183","volume":"11","author":"BA Hanks","year":"2005","unstructured":"Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM (2005) Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 11:130\u2013137. doi:10.1038\/nm1183","journal-title":"Nat Med"},{"key":"2027_CR14","doi-asserted-by":"publisher","first-page":"10528","DOI":"10.1158\/0008-5472.CAN-07-0833","volume":"67","author":"N Lapteva","year":"2007","unstructured":"Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM (2007) Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Can Res 67:10528\u201310537. doi:10.1158\/0008-5472.CAN-07-0833","journal-title":"Can Res"},{"key":"2027_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/00912700122010771","volume":"41","author":"JD Iuliucci","year":"2001","unstructured":"Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T, Berger HJ (2001) Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41:870\u2013879","journal-title":"J Clin Pharmacol"},{"key":"2027_CR16","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673\u20131683. doi:10.1056\/NEJMoa1106152","journal-title":"N Engl J Med"},{"key":"2027_CR17","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.95.18.10437","volume":"95","author":"T Clackson","year":"1998","unstructured":"Clackson T, Yang W, Rozamus LW et al (1998) Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95:10437\u201310442","journal-title":"Proc Natl Acad Sci USA"},{"key":"2027_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"GL Wright Jr","year":"1996","unstructured":"Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326\u2013334","journal-title":"Urology"},{"key":"2027_CR19","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Can Res 57:3629\u20133634","journal-title":"Can Res"},{"key":"2027_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. doi:10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2027_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159. doi:10.1200\/JCO.2007.12.4487","journal-title":"J Clin Oncol"},{"key":"2027_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14653240600620093","volume":"8","author":"D Xing","year":"2006","unstructured":"Xing D, Decker WK, Li S et al (2006) AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy 8:95\u2013104. doi:10.1080\/14653240600620093","journal-title":"Cytotherapy"},{"key":"2027_CR23","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.vaccine.2006.01.029","volume":"24","author":"WK Decker","year":"2006","unstructured":"Decker WK, Xing D, Li S et al (2006) Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine 24:3203\u20133216. doi:10.1016\/j.vaccine.2006.01.029","journal-title":"Vaccine"},{"key":"2027_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","volume":"33","author":"HI Scher","year":"2015","unstructured":"Scher HI, Heller G, Molina A et al (2015) Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 33:1348\u20131355. doi:10.1200\/JCO.2014.55.3487","journal-title":"J Clin Oncol"},{"key":"2027_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1200\/JCO.2003.04.163","volume":"21","author":"BI Rini","year":"2003","unstructured":"Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21:99\u2013105","journal-title":"J Clin Oncol"},{"key":"2027_CR26","first-page":"1738","volume":"5","author":"EJ Small","year":"1999","unstructured":"Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5:1738\u20131744","journal-title":"Clin Cancer Res"},{"key":"2027_CR27","unstructured":"Small E, Demkow T, Gerritsen WR et al (2009) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: Proceedings genitourinary cancer symposium. Orlando, 26\u201328 February 2009 (abstract 7)"},{"key":"2027_CR28","unstructured":"Higano CS, Saad F, Curti BD et al (2009) A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). In: Proceedings genitourinary cancers symposium. Orlando, 26\u201328 February 2009 (abstract LBA150)"},{"key":"2027_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","volume":"62","author":"NA Sheikh","year":"2013","unstructured":"Sheikh NA, Petrylak D, Kantoff PW et al (2013) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62:137\u2013147. doi:10.1007\/s00262-012-1317-2","journal-title":"Cancer Immunol Immunother"},{"key":"2027_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju268","author":"L Fong","year":"2014","unstructured":"Fong L, Carroll P, Weinberg V et al (2014) Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. doi:10.1093\/jnci\/dju268","journal-title":"J Natl Cancer Inst"},{"key":"2027_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700\u2013712. doi:10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"key":"2027_CR32","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. doi:10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"2027_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099\u20131105. doi:10.1200\/JCO.2009.25.0597","journal-title":"J Clin Oncol"},{"key":"2027_CR34","doi-asserted-by":"publisher","first-page":"18192","DOI":"10.18632\/oncotarget.4145","volume":"6","author":"M Podrazil","year":"2015","unstructured":"Podrazil M, Horvath R, Becht E et al (2015) Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6:18192\u201318205. doi:10.18632\/oncotarget.4145","journal-title":"Oncotarget"},{"key":"2027_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","volume":"70","author":"K Yoshimura","year":"2016","unstructured":"Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H (2016) A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer. Eur Urol 70:35\u201341. doi:10.1016\/j.eururo.2015.12.050","journal-title":"Eur Urol"},{"key":"2027_CR36","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","volume":"27","author":"DG McNeel","year":"2009","unstructured":"McNeel DG, Dunphy EJ, Davies JG et al (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27:4047\u20134054. doi:10.1200\/JCO.2008.19.9968","journal-title":"J Clin Oncol"},{"key":"2027_CR37","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1089\/104303401753204535","volume":"12","author":"BJ Miles","year":"2001","unstructured":"Miles BJ, Shalev M, Aguilar-Cordova E et al (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12:1955\u20131967. doi:10.1089\/104303401753204535","journal-title":"Hum Gene Ther"},{"key":"2027_CR38","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/10430349950018229","volume":"10","author":"JR Herman","year":"1999","unstructured":"Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT (1999) In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10:1239\u20131249. doi:10.1089\/10430349950018229","journal-title":"Hum Gene Ther"},{"key":"2027_CR39","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI44327","volume":"121","author":"P Narayanan","year":"2011","unstructured":"Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM (2011) A composite MyD88\/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Investig 121:1524\u20131534. doi:10.1172\/JCI44327","journal-title":"J Clin Investig"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-017-2027-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:10:16Z","timestamp":1659057016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-017-2027-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,12]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2027-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,12]]},"assertion":[{"value":"7 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G. Sonpavde: Consultant for Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, Astrazeneca, Merck, Genentech, Argos, Agensys; research support to institution from Bellicum, Bayer, Onyx, Celgene, Boehringer-Ingelheim, Merck, Pfizer; author for Uptodate; speaker for Clinical Care Options. J.D. McMannis, Y. Bai, M. Seethammagari, J.M.C. Bull, V. Hawkins, T. Dancsak, N. Lapteva, J.M. Levitt: funding to institution by Bellicum Pharmaceuticals, Inc. D.M. Spencer, A. Moseley, K.M. Slawin: employed by and shareholders of Bellicum Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the institutional review boards (IRBs) at the University of Texas, Houston, Texas.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"All participants provided written informed consent. The trial was registered at ClinicalTrials.gov under the identification NCT00868595.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The trial was funded and sponsored by Bellicum Pharmaceuticals, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}}]}}